Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC

Testosterone is the canonical growth factor of prostate cancer but can paradoxically suppress its growth when present at supraphysiological levels. We have previously demonstrated that the cyclical administration of supraphysiological androgen (SPA), termed bipolar androgen therapy (BAT), can result...

Descripción completa

Detalles Bibliográficos
Autores principales: Sena, Laura A., Kumar, Rajendra, Sanin, David E., Thompson, Elizabeth A., Rosen, D. Marc, Dalrymple, Susan L., Antony, Lizamma, Yang, Yuhan, Gomes-Alexandre, Carolina, Hicks, Jessica L., Jones, Tracy, Bowers, Kiara A., Eskra, Jillian N., Meyers, Jennifer, Gupta, Anuj, Skaist, Alyza, Yegnasubramanian, Srinivasan, Luo, Jun, Brennen, W. Nathaniel, Kachhap, Sushant K., Antonarakis, Emmanuel S., De Marzo, Angelo M., Isaacs, John T., Markowski, Mark C., Denmeade, Samuel R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9711876/
https://www.ncbi.nlm.nih.gov/pubmed/36194476
http://dx.doi.org/10.1172/JCI162396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9711876/
https://www.ncbi.nlm.nih.gov/pubmed/36194476
http://dx.doi.org/10.1172/JCI162396

Ejemplares similares